Transparency

FAST (Foundation for Angelman Syndrome Therapeutics) is an Internal Revenue Code Section 501(c)(3) nonprofit charity, exempt from federal taxation. Transparency is both a requirement and an obligation that is also vitally important to our members.

2019

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2019 Audited Financial Statements as well as a link to the FAST 2019 Federal Tax Return.  The FAST calendar year ended 2019 audited financials show total revenue of $4,336,872 and total expenses of $5,128,132. Additionally, there is $1,968,564 in non-operating gains recognized on FAST’s investment in GeneTx Biotherapeutics, LLC. Expenses of $5,128,132 include research funding in the amount of $4,126,259 and $734,878 in other program-related expenses. Fundraising expenses totaled $183,057, and general administrative expenses incurred by FAST in 2019 were $83,938.  $8,751,037 in net assets as well as $3,197,375 in grants payable were held at year-end, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. Notably, all compensation shown on Part VII of the FAST 990 is related to reportable compensation from our related organization, GeneTX Biotherapeutics, and properly classified in Column E.   For detailed information, please see the FAST 2019 Audited Financials and  FAST Federal Tax Return.

2018

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2018 Audited Financial Statements as well as a link to the FAST 2018 Federal Tax Return.  The FAST calendar year ended 2018 audited financials show total revenue of $5,431,132 and total expenses of $3,104,807. Expenses of $3,104,807 include research funding in the amount of $2,260,991 and $414,253 in other program-related expenses.  Fundraising expenses totaled $203,437, and general administrative expenses incurred by FAST in 2018 were $226,126.  $7,573,733 in net assets as well as $1,174,132 in grants payable were held at year-end, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see FAST 2018 Audited Financials and FAST Federal Tax Return.

2017

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2017 Audited Financial Statements as well as a link to the FAST 2017 Federal Tax Return.  The FAST calendar year ended 2017 audited financials show total revenue of $8,845,782 and total expenses of $5,739,913. Expenses of $5,739,913 include research funding in the amount of $5,218,272 and $232,586 in other program-related expenses.  Fundraising expenses totaled $191,049, and general administrative expenses incurred by FAST in 2017 were $98,006.  $5,247,408 in net assets as well as $2,462,895 in grants payable were held at year-end, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see  FAST 2017 Audited Financials and  FAST  Federal Tax Return.

2016

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2016 Audited Financial Statements as well as a link to the FAST 2016 Federal Tax Return.  The FAST calendar year ended 2016 audited financials show total revenue of $4,475,739 and total expenses of $3,529,159. Expenses of $3,529,159 include research funding in the amount of $3,039,187 and $63,381 in other program-related expenses.  Fundraising expenses totaled $313,486, and general administrative expenses incurred by FAST in 2016 were $113,105.  $2,141,539 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see FAST 2016 Audited Financials and Federal Tax Return.

2015

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2015 Audited Financial Statements as well as a link to the FAST 2015 Federal Tax Return.  The FAST calendar year ended 2015 audited financials show total revenue of $1,121,173 and total expenses of $1,348,143. Expenses of $1,348,143 include research funding in the amount of $1,116,067 and $125,910 in other program-related expenses.  Fundraising expenses totaled $82,549, and general administrative expenses incurred by FAST in 2015 were $23,617.  $1,194,959 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see FAST 2015 Audited Financials and Federal Tax Return.

2014

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2014 Audited Financial Statement as well as a link to the FAST 2014 Federal Tax Return.  The FAST calendar year ended 2014 audited financials show total revenue of $1,576,826 and total expenses of $1,256,386. Expenses of $1,256,386 include research funding in the amount of $1,042,667 and $112,293 in other program-related expenses.  Fundraising expenses totaled $78,121, and general administrative expenses incurred by FAST in 2014 were $23,305.  $1,571,929 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST.  For detailed information, please see FAST 2014 Audited Financials and Federal Tax Return.

2013

Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2013 Audited Financial Statement as well as a link to the FAST 2013 Federal Tax Return. The FAST calendar year ended 2013 audited financials show total revenue of $913,798 and total expenses of $979,548. Expenses of $979,548 include research funding in the amount of $808,469 and $63,544 in other program-related expenses. Total general administrative expenses incurred by FAST in 2013 were $24,509. $1,101,489 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see FAST 2013 Audited Financials and Federal Tax Return 2013.

2012

The FAST calendar year ended 2012 audited financials show total revenue of $955,052 and total expenses of $391,600. Expenses of $391,600 include research funding in the amount of $253,890 and $58,550 in other program-related expenses.  Total general administrative expenses incurred by FAST in 2012 were $34,920, which included $17,476 of general administrative expenses and temporarily restricted funds of $17,444 for family travel expenses incurred in the Minocycline Clinical Trial.  $1,167,239 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For further details visit the following hyperlinks; Audited Financial Statements 2012 & Federal Tax Return 2012.

2011

The FAST calendar year ended 2011 audited financials show total revenue of $639,525 and total expenses of $207,400. Expenses of $207,400 include research funding in the amount of $125,110 and other program-related expenses of $41,561.  Total general administrative expenses incurred by FAST in 2011 were $6,621.  $603,787 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For further details visit the following hyperlinks; Audited Financial Statements 2011 & Federal Tax Return 2011.

FAST (Foundation for Angelman Syndrome Therapeutics) is an Internal Revenue Code Section 501(c)(3), a nonprofit charity, exempt from federal taxation. Transparency is both a requirement and an obligation that is also vitally important to our members.

View FAST’s W9 form.

View our Conflict of Interest & Whistleblower Policy

X
X